肾臟生物製造商市场规模、份额、成长分析（按生物标记、诊断技术、地区）- 产业预测，2025-2032 年

2023年肾臟生物製造商的全球市场规模预计为12.9亿美元，从2024年的13.9亿美元增长到2032年的24.9亿美元，预测期间（2025-2032年）预计复合年增长率为7.6%。

由于对肾臟疾病精确诊断工具和客製化治疗策略的需求不断增长，全球肾臟生物标记市场正处于强劲成长轨道。生物标记是肾功能的重要指标，有助于早期发现和监测慢性肾臟病、急性肾损伤等疾病。由于人口老化以及糖尿病和高血压等生活方式因素，肾臟疾病的盛行率不断增加，进一步推动了这项需求。生物标记检测的技术进步极大地提高了检测的准确性和可靠性，促进了明智的临床决策。然而，它面临着肾臟疾病的复杂性、需要多种生物标记进行综合评估、监管障碍以及需要标准化检测通讯协定等挑战，导致其在临床实践中的广泛使用成为障碍。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

肾臟生物製造商市场规模：依生物标记分类

• 市场概况
• 功能性生物标记
  • 血清肌酸酐
  • 血清胱Cystatin C
  • 尿液白蛋白
• 上调蛋白质
  • 嗜中性白血球明胶酶相关脂质运载蛋白
  • 肾损伤分子1
  • 白细胞介素-18
• 其他的

肾臟生物製造商市场规模：依诊断技术

• 市场概况
• 酵素免疫分析法测定法 (ELISA)
• 粒子增强免疫检测(PETIA)
• 比色分析
• 化学冷光酵素免疫分析法(CLIA)
• 液相层析法质谱法 (LS-MS)

肾臟生物製造商市场规模：按最终用户划分

• 市场概况
• 诊断实验室
• 门诊
• 研究中心
• 医院

肾臟生物製造商市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
• 收益与前一年同期比较（2022-2024）

主要企业简介

• Abbott Laboratories
• BioPorto Diagnostics AS
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• SEKISUI MEDICAL CO., LTD.
• BioMerieux SA
• Sphingotec GmbH
• Randox Laboratories Ltd
• Siemens Healthineers AG
• Enzo Life Sciences, Inc.
• Beckman Coulter, Inc.（Danaher Corporation）
• Fujirebio Inc.
• Bio-Rad Laboratories, Inc.
• Nova Biomedical Corporation
• Sysmex Corporation
• ACON Laboratories, Inc.
• Gold Standard Diagnostics Corp.
• R&D Systems, Inc.（Bio-Techne Corporation）
• Dako（Agilent Technologies, Inc.）
• DiaSorin SpA

结论和建议

Global Renal Biomakers Market size was valued at USD 1.29 billion in 2023 and is poised to grow from USD 1.39 billion in 2024 to USD 2.49 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The global renal biomarkers market is on a robust growth trajectory, driven by an escalating demand for precise diagnostic tools and tailored treatment strategies for kidney diseases. As key indicators of renal function, these biomarkers enhance the early detection and monitoring of conditions such as chronic kidney disease and acute kidney injury. The rising prevalence of renal diseases, exacerbated by aging populations and lifestyle factors like diabetes and hypertension, propels this demand further. Technological advancements in biomarker detection have significantly improved test accuracy and reliability, facilitating informed clinical decision-making. However, the market faces challenges, including the complexities of renal conditions necessitating multiple biomarkers for comprehensive assessments, regulatory hurdles, and the need for standardized testing protocols, which can hinder widespread adoption in clinical settings.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Renal Biomakers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Renal Biomakers Market Segmental Analysis

Global Renal Biomakers Market is segmented on the basis of type, end-user, and region. By type, the market is segmented into functional biomarkers, up-regulated proteins, and other biomarker types. By end user, the market is segmented into hospitals, diagnostic laboratories, and other end users. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Renal Biomakers Market

One of the primary factors propelling the Global Renal Biomarkers market is the rising prevalence of renal diseases, such as chronic kidney disease (CKD), acute kidney injury (AKI), and kidney failure. As the rates of these conditions continue to increase, there is a heightened need for renal biomarkers, which are essential for the early detection, precise diagnosis, and effective monitoring of kidney-related ailments. These biomarkers are instrumental in facilitating timely medical interventions and enhancing patient outcomes, thereby significantly driving market growth and reinforcing their critical importance in healthcare strategies aimed at managing renal health.

Restraints in the Global Renal Biomakers Market

The Global Renal Biomarkers market faces various restraints, particularly due to regulatory challenges. The intricate and continuously changing regulatory environment surrounding biomarkers poses hurdles in acquiring necessary approvals and adhering to stringent quality and safety standards. This process can be lengthy and demand significant resources, ultimately impeding market growth and stifling innovation within the industry. Navigating these complex regulatory pathways presents a significant barrier for companies striving to develop and commercialize renal biomarkers, potentially delaying their entry into the market and affecting overall advancements in renal healthcare solutions.

Market Trends of the Global Renal Biomakers Market

The Global Renal Biomarkers market is witnessing a significant trend towards the increasing adoption of personalized medicine, which is reshaping patient care in nephrology. Healthcare providers are increasingly leveraging renal biomarkers to create individualized treatment strategies that take into account each patient's unique characteristics and the progression of their disease. This personalized approach not only enhances the efficacy of targeted therapies but also helps improve overall patient outcomes, fostering a paradigm shift in renal disease management. As a result, the market is expected to expand rapidly, driven by innovations in biomarker research and the growing emphasis on customized healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Renal Biomakers Market Size by Biomarker & CAGR (2025-2032)

• Market Overview
• Functional Biomarker
  • Serum Creatinine
  • Serum Cystatin C
  • Urine Albumin
• Up-Regulated Proteins
  • Neutrophil Gelatinase-Associated Lipocalin
  • Kidney Injury Molecule-1
  • Interleukin-18
• Others

Global Renal Biomakers Market Size by Diagnostic Technique & CAGR (2025-2032)

• Market Overview
• Enzyme Linked Immunosorbent Assay (ELISA)
• Particle-Enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography-Mass Spectrometry (LS-MS)

Global Renal Biomakers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Diagnostic Labs
• Outpatient Clinics
• Research Centers
• Hospitals

Global Renal Biomakers Market Size & CAGR (2025-2032)

• North America (Biomarker, Diagnostic Technique, End User)
  • US
  • Canada
• Europe (Biomarker, Diagnostic Technique, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker, Diagnostic Technique, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker, Diagnostic Technique, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker, Diagnostic Technique, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioPorto Diagnostics AS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SEKISUI MEDICAL CO., LTD.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sphingotec GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzo Life Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter, Inc. (Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nova Biomedical Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACON Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gold Standard Diagnostics Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R&D Systems, Inc. (Bio-Techne Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dako (Agilent Technologies, Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations